Inogen (INGN) PT Lowered to $111.00

Inogen (NASDAQ:INGN) had its price objective lowered by Needham & Company LLC from $191.00 to $111.00 in a report released on Wednesday, May 8th, FinViz reports. The brokerage currently has a strong-buy rating on the medical technology company’s stock.

Other analysts also recently issued research reports about the stock. Piper Jaffray Companies decreased their price objective on shares of Inogen from $290.00 to $185.00 and set an overweight rating for the company in a research note on Wednesday, February 27th. JPMorgan Chase & Co. decreased their price objective on shares of Inogen to $175.00 and set an overweight rating for the company in a research note on Wednesday, February 27th. Zacks Investment Research raised shares of Inogen from a hold rating to a buy rating and set a $169.00 price objective for the company in a research note on Tuesday, February 5th. ValuEngine downgraded shares of Inogen from a hold rating to a sell rating in a research note on Thursday, February 28th. Finally, BidaskClub downgraded shares of Inogen from a hold rating to a sell rating in a research note on Wednesday, March 6th. Two analysts have rated the stock with a sell rating, three have given a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of Hold and a consensus target price of $121.60.

Shares of NASDAQ:INGN opened at $64.47 on Wednesday. The company has a quick ratio of 6.70, a current ratio of 7.35 and a debt-to-equity ratio of 0.02. Inogen has a 12 month low of $62.83 and a 12 month high of $287.79. The stock has a market capitalization of $1.40 billion, a P/E ratio of 28.03, a price-to-earnings-growth ratio of 2.51 and a beta of 1.39.

Inogen (NASDAQ:INGN) last announced its quarterly earnings results on Tuesday, May 7th. The medical technology company reported $0.24 EPS for the quarter, missing the Zacks’ consensus estimate of $0.29 by ($0.05). Inogen had a net margin of 12.56% and a return on equity of 15.59%. The business had revenue of $90.20 million during the quarter, compared to the consensus estimate of $89.69 million. During the same period in the previous year, the business posted $0.48 EPS. The firm’s revenue was up 14.1% on a year-over-year basis. On average, sell-side analysts forecast that Inogen will post 1.63 earnings per share for the current year.

Several large investors have recently modified their holdings of INGN. Harel Insurance Investments & Financial Services Ltd. purchased a new position in Inogen during the first quarter valued at approximately $25,000. Fifth Third Bancorp increased its holdings in Inogen by 115.0% during the first quarter. Fifth Third Bancorp now owns 286 shares of the medical technology company’s stock valued at $27,000 after buying an additional 153 shares during the period. Hanson McClain Inc. purchased a new position in Inogen during the first quarter valued at approximately $50,000. South Dakota Investment Council purchased a new position in Inogen during the fourth quarter valued at approximately $87,000. Finally, First Mercantile Trust Co. purchased a new position in Inogen during the fourth quarter valued at approximately $99,000. 98.63% of the stock is currently owned by institutional investors and hedge funds.

About Inogen

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Read More: What is included in the gross domestic product?

Analyst Recommendations for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.